Business
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
THOUSAND OAKS, Calif., May 05, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Atara’s active Investigational New Drug (IND) applications for the EBVALLO™ (tabelecleucel) program.
About this update from Atara Biotherapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3000,"height":912,"url":"https://media.zenfs.com/en/business-wire.com/7df8ea3236aac2ec7cdcc3e81d1369b9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2HdHwNY61jNcsYxlzbBmrA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI5MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7df8ea3236aac2ec7cdcc3e81d1369b9","width":960,"height":292},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/0p9KQbU21kEHiYl5uYBedA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/7df8ea3236aac2ec7cdcc3e81d1369b9","width":1200,"height":365}},"lazy":false},{"type":"text","content":"FDA lifts clinical hold enabling resumption of clinical trials","length":62,"tagName":"p","attribs":{}},{"type":"text","content":"FDA has granted a Type A Meeting to discuss path forward for BLA","length":64,"tagName":"p","attribs":{}},{"type":"text","content":"THOUSAND OAKS, Calif., May 05, 2025--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Atara’s active Investigational New Drug (IND) applications for the EBVALLO™ (tabelecleucel) program.","length":488,"tagName":"p"},{"type":"text","content":""We are very pleased to have addressed the FDA’s questions, and this has enabled the FDA to lift the clinical holds," said Cokey Nguyen Ph.D., President and Chief Executive Officer of Atara. "We are working closely with our partner Pierre Fabre Laboratories and our clinical trial sites and anticipate resuming enrollment and treatment of patients as soon as possible."","length":389,"tagName":"p"},{"type":"text","content":"In January 2025, the EBVALLO™ (tabelecleucel) program was placed on clinical hold. The clinical hold was directly linked to GMP compliance issues identified during the pre-license inspection of the third-party manufacturing facility referenced in the Complete Response Letter (CRL) for EBVALLO™ that was announced on January 16, 2025.","length":334,"tagName":"p"},{"type":"te...